Pay-for-performance risk shares 'only way forward' for drug market access
This article was originally published in SRA
Executive Summary
It has long been acknowledged that risk-sharing agreements between pharmaceutical manufacturers and payers, including the popular simple discount approach, are becoming ever more essential for getting drugs market access. However, the more complicated outcomes-based risk sharing approach, often referred to as 'pay-for-performance', is gaining traction and, according to some, could be the 'only way forward' for certain high-priced products.